Literature DB >> 12659933

Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha.

Alejandro Sánchez1, María Tobío, Libia González, Angels Fabra, María J Alonso.   

Abstract

The development of new interferon-alpha (IFN-alpha) delivery strategies is a key issue in order to simplify its administration and improve its therapeutic effects, while reducing its dose-related side effects. One of the most attractive approaches towards this aim is the encapsulation of IFN-alpha into poly(lactic-glycolic acid) (PLGA) microspheres. Nevertheless, the stability of IFN-alpha released from these microspheres has been identified as one of the most important concerns in relation to the potential of this approach. Being conscious of this problem, we have used new strategies for the encapsulation of IFN-alpha into biodegradable micro- and nanoparticles. We chose poloxamer 188 as a stabilizing agent and encapsulated IFN-alpha within PLGA/poloxamer blend microspheres prepared by an oil-in-oil solvent extraction technique and also within PLGA micro- and nanospheres containing poloxamer, prepared by the water-in-oil-in-water solvent evaporation technique. The results showed that these techniques led to the efficient encapsulation of IFN-alpha and the modulation of their particle size, ranging from nanospheres (280 nm) to 40 microm-microspheres. These systems exhibit a similar pattern of release that is characterized by an initial burst (2-24% IFN-alpha released, as determined by ELISA) followed by small pulses of immunoenzymatically detected IFN-alpha for up to 1 month. The maintenance of the structural integrity and bioactivity of the protein was confirmed using a cytostasis bioassay. The results showed that the antiproliferative activity of the IFN-alpha varied depending on the formulation. More specifically, PLGA/poloxamer blend microspheres were able to provide significant amounts of active IFN-alpha for up to 96 days. This new IFN-alpha delivery system opens up possibilities to improve present IFN-alpha-based therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12659933     DOI: 10.1016/s0928-0987(03)00019-8

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  22 in total

Review 1.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

2.  Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination.

Authors:  Sang-Jun Ha; Su-Hyung Park; Hye-Ju Kim; Seung-Chul Kim; Hyang-Ju Kang; Eun-Gae Lee; Soon-Geon Kwon; Byong-Moon Kim; Sung-Hee Lee; Won-Bae Kim; Young-Chul Sung; Sang-Nae Cho
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 3.  Advances in immunotherapy delivery from implantable and injectable biomaterials.

Authors:  David G Leach; Simon Young; Jeffrey D Hartgerink
Journal:  Acta Biomater       Date:  2019-02-13       Impact factor: 8.947

4.  Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres.

Authors:  Jamal S Lewis; Chris Roche; Ying Zhang; Todd M Brusko; Clive H Wasserfall; Mark Atkinson; Michael J Clare-Salzler; Benjamin G Keselowsky
Journal:  J Mater Chem B       Date:  2014-05-07       Impact factor: 6.331

5.  Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with beta-amyloid fibrils.

Authors:  Ipek Baysal; Samiye Yabanoglu-Ciftci; Yeliz Tunc-Sarisozen; Kezban Ulubayram; Gulberk Ucar
Journal:  J Neural Transm (Vienna)       Date:  2013-02-19       Impact factor: 3.575

6.  Transport and delivery of interferon-α through epithelial tight junctions via pH-responsive poly(methacrylic acid-grafted-ethylene glycol) nanoparticles.

Authors:  Mary Caldorera-Moore; Julia E Vela Ramirez; Nicholas A Peppas
Journal:  J Drug Target       Date:  2019-03-01       Impact factor: 5.121

7.  Composite hydrogel formulations of stratifin to control MMP-1 expression in dermal fibroblasts.

Authors:  Elham Rahmani-Neishaboor; John Jackson; Helen Burt; Aziz Ghahary
Journal:  Pharm Res       Date:  2009-06-17       Impact factor: 4.200

8.  Emulsification/internal gelation as a method for preparation of diclofenac sodium-sodium alginate microparticles.

Authors:  Mahmoud M Ahmed; Saleh Abd El-Rasoul; Sayed H Auda; Mohamed A Ibrahim
Journal:  Saudi Pharm J       Date:  2011-09-08       Impact factor: 4.330

9.  Chitosan solution enhances the immunoadjuvant properties of GM-CSF.

Authors:  David A Zaharoff; Connie J Rogers; Kenneth W Hance; Jeffrey Schlom; John W Greiner
Journal:  Vaccine       Date:  2007-11-05       Impact factor: 3.641

Review 10.  Localized Interleukin-12 for Cancer Immunotherapy.

Authors:  Khue G Nguyen; Maura R Vrabel; Siena M Mantooth; Jared J Hopkins; Ethan S Wagner; Taylor A Gabaldon; David A Zaharoff
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.